Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP regarding QURE
Investors should be aware of the ongoing securities fraud class action lawsuit filed against uniQure N.V. (NASDAQ: QURE) by Kessler Topaz Meltzer & Check, LLP. The lawsuit targets investors who bought or obtained uniQure ordinary shares between September 24, 2025, and October 31, 2025, known as the Class Period. The case, identified as Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was lodged in the United States District Court for the Southern District of New York. An essential deadline for investors who bought or acquired uniQure ordinary shares during this period is to potentially become the lead plaintiff for the class by April 13, 2026.
uniQure, a biotech firm dedicated to gene therapies for rare diseases, especially Huntington’s disease (HD), is headquartered in The Netherlands. Their primary focus is on AMT-130, a revolutionary gene therapy designed to slow down the progression of HD, an inherited genetic disorder culminating in the breakdown of nerve cells in the brain. This disorder leads to motor and cognitive impairments alongside psychiatric complications, with no existing cure or method to halt its progression. AMT-130 is among a select few drugs undergoing tests aimed at impeding HD’s advancement. The Company had finished enrolling patients in two dose-escalating Phase I/II clinical trials for AMT-130 by March 2022, referred to as the Pivotal Study.
The Defendants disclosed that the U.S. Food and Drug Administration (FDA) had agreed that uniQure could compare the results of the Pivotal Study to an external historical data set, Enroll-HD, for possible inclusion in their Biologic License Application (BLA) submission seeking approval to administer AMT-130 to HD patients. CEO Matthew Kapusta assured investors of aligning with FDA directives during investor calls in June and July 2025. Subsequently, on September 24, 2025, the Company announced significant results from the Pivotal Study emphasizing a “mean reduction from baseline in cerebrospinal neurofilament light protein” (CSF NfL), highlighting it as a reliable biomarker for neurodegeneration. Investors were led to believe that AMT-130 effectively slowed neurodegeneration in HD patients and that a BLA submission was imminent based on the observed outcomes compared to data from ENROLL-HD.
Market response to these claims was significant, with the closing price of uniQure ordinary shares skyrocketing to $47.50 per share from $13.66 per share on September 23, 2025, marking an almost 250% increase. By October 29, 2025, the shares were trading above $70.00 each. Leveraging this surge in share value, uniQure publicly issued over 5.7 million uniQure ordinary shares and 500,000 pre-funded warrants shortly after the Pivotal Study results, known as the September 2025 Offering. Despite the uncertainty surrounding the future of AMT-130 until FDA discussions, uniQure justified the September 2025 Offering in the prospectus supplement as crucial for “commercialization readiness activities.”